Marimed (MRMD) Net Income towards Common Stockholders Growth (1y) (2012 - 2026)
Marimed (MRMD) Net Income towards Common Stockholders Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Marimed | 30.77 Mn | 22.33 Mn | 16.23 Mn | -155.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -155.99% |
| Mar 31, 2026 | 31.25% |
| Dec 31, 2025 | 43.84% |
| Sep 30, 2025 | -197.07% |
| Jun 30, 2025 | 22.51% |
| Mar 31, 2025 | -324.07% |
| Dec 31, 2024 | 18.49% |
| Sep 30, 2024 | 76.81% |
| Jun 30, 2024 | -75.29% |
| Mar 31, 2024 | -94.58% |
| Dec 31, 2023 | -313.50% |
| Sep 30, 2023 | -256.83% |
| Jun 30, 2023 | -149.31% |
| Mar 31, 2023 | -115.66% |
| Dec 31, 2022 | 174.13% |
| Sep 30, 2022 | 28.21% |
| Jun 30, 2022 | -75.02% |
| Mar 31, 2022 | -1.60% |
| Dec 31, 2021 | -202.02% |
| Sep 30, 2021 | 25.19% |